MedTrace Logo

A Study to Assess the Safety and Efficacy of Enantone (Leuprorelin) in Central Precocious Puberty (CPP) Among Chinese Participants

NCT02993926 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 108

Last updated 2022-03-16

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate the long-term safety and efficacy of Enantone in the treatment of CPP in Chinese participants.

Conditions

  • Central Precocious Puberty

Interventions

DRUG

Enantone

Enantone suspension for injection

DRUG

GnRH agonist

A non-Enantone GnRH agonist

Sponsors & Collaborators

Principal Investigators

  • Medical Director Clinical Science · Takeda

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-06-24
Primary Completion
2018-09-30
Completion
2018-09-30

Countries

  • China

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02993926 on ClinicalTrials.gov